tiprankstipranks
Trending News
More News >
CleanSpace Holdings Ltd. (AU:CSX)
ASX:CSX
Australian Market

CleanSpace Holdings Ltd. (CSX) AI Stock Analysis

Compare
8 Followers

Top Page

AU:CSX

CleanSpace Holdings Ltd.

(Sydney:CSX)

Select Model
Select Model
Select Model
Neutral 43 (OpenAI - 5.2)
Rating:43Neutral
Price Target:
AU$0.55
▼(-19.12% Downside)
Action:ReiteratedDate:11/28/25
CleanSpace Holdings Ltd. is currently facing significant financial and technical challenges. The most impactful factors are the ongoing profitability issues and weak cash flow performance, compounded by bearish technical indicators. The negative P/E ratio and lack of dividend yield further detract from the stock's valuation appeal. Overall, the stock's outlook is cautious, with financial instability and negative market momentum being the primary concerns.
Positive Factors
High Gross Margin
A 74.76% gross margin indicates very efficient product-level economics and pricing power in its respirator products. This provides a durable cushion to absorb operating expenses, supports reinvestment in R&D and go-to-market, and improves the odds of achieving profitability as revenue scales.
Diversified Revenue Model
Multiple revenue streams—new product sales, recurring replacement parts/filters, service and training contracts and distributor channels—reduce single-channel risk. Recurring parts and service revenue enhance predictability and lifetime customer value, supporting steadier cash generation over time.
Manageable Leverage
A debt-to-equity of 0.24 signals conservative financial leverage, leaving balance sheet flexibility to fund growth or weather downturns without heavy interest burdens. Low relative debt reduces refinancing risk and preserves capacity for strategic investments or working capital needs.
Negative Factors
Negative Profitability
Sustained negative net and EBIT margins show the company has not yet converted strong unit economics into operating profits. Continued losses undermine retained earnings, increase reliance on external capital, and constrain the firm's ability to self-fund growth or reward shareholders over the medium term.
Weak Cash Flow Conversion
Declining free cash flow growth and low operating-cash-flow-to-net-income ratios indicate difficulty converting reported results into usable cash. This limits capacity for capex, inventory build or service expansion, raising liquidity risk and increasing the likelihood of future external financing or dilution.
Limited Scale
A small headcount (55 employees) suggests constrained operational scale across manufacturing, sales and service. Limited scale can slow new market penetration, hamper large contract execution, and delay achieving economies of scale, leaving the company vulnerable to larger competitors in key industrial channels.

CleanSpace Holdings Ltd. (CSX) vs. iShares MSCI Australia ETF (EWA)

CleanSpace Holdings Ltd. Business Overview & Revenue Model

Company DescriptionCleanSpace Holdings Limited engages in the design, manufacture, and sale of respirators and related products and services for healthcare and industrial employers worldwide. It offers CleanSpace HALO, a personal respiratory protection for healthcare; CleanSpace ULTRA, a personal respiratory protection for face/eye protection and water tolerance; CleanSpace2, a personal respiratory protection for workers in general industrial environments; and CleanSpace EX for personal protection for people working in explosive environments. The company also provides accessories and consumable products comprising masks, filters, docking stations, cleaning and storage products, car chargers, biohoods, half mask and bio mask exhalation adaptors, unit id panels, mask id badges, mask decal, helmet hook strap, hoods, backpacks, full face mask quantitative fit test, full face mask spectacle kits, visor protectors, head harness, grommet, and spares. It serves mining, welding, construction, laboratory, dental, wastewater, and healthcare and first responder's industries. CleanSpace Holdings Limited was founded in 2009 and is based in St Leonards, Australia.
How the Company Makes MoneyCleanSpace Holdings generates revenue primarily through the sale of its respiratory protection equipment and accessories. The company has a diversified revenue model that includes direct sales to customers, distribution partnerships, and contracts with government and healthcare institutions. Key revenue streams consist of product sales, recurring sales from replacement parts and filters, and service agreements for maintenance and training on the use of their equipment. Strategic partnerships with distributors and industry leaders further enhance market reach and contribute to earnings, while ongoing investments in research and development help to innovate and expand their product offerings, attracting new customers and retaining existing ones.

CleanSpace Holdings Ltd. Financial Statement Overview

Summary
CleanSpace Holdings Ltd. faces significant financial challenges, with ongoing profitability issues and weak cash flow performance. Revenue growth has shown recent improvement, but the company struggles with negative margins and low returns on equity. The balance sheet is moderately leveraged, providing some stability, but overall financial health remains a concern.
Income Statement
45
Neutral
CleanSpace Holdings Ltd. has experienced fluctuating revenue growth, with a recent positive growth rate of 12.25% after a period of decline. However, profitability remains a concern with negative net profit margins and EBIT margins, indicating ongoing operational challenges. The gross profit margin is relatively strong at 74.76%, suggesting effective cost management despite overall losses.
Balance Sheet
55
Neutral
The company's debt-to-equity ratio is moderate at 0.24, indicating a balanced approach to leveraging. However, the return on equity is negative, reflecting the company's struggle to generate profits from shareholders' equity. The equity ratio is not provided, but the overall financial stability is moderate with manageable debt levels.
Cash Flow
40
Negative
Cash flow performance is weak, with a significant decline in free cash flow growth. The operating cash flow to net income ratio is low, indicating challenges in converting income into cash. However, the free cash flow to net income ratio is relatively high, suggesting some efficiency in cash management despite overall cash flow issues.
BreakdownTTMJun 2025Jun 2024Jun 2023Jun 2022Jun 2021
Income Statement
Total Revenue20.66M19.76M15.72M12.09M13.36M49.93M
Gross Profit9.47M14.78M11.36M-5.16M9.75M40.27M
EBITDA-1.07M-824.55K-3.49M-10.55M-14.10M17.15M
Net Income1.76M-478.28K-3.13M-8.13M-11.28M11.39M
Balance Sheet
Total Assets26.92M27.57M26.05M28.98M38.36M50.72M
Cash, Cash Equivalents and Short-Term Investments9.83M10.47M9.76M12.16M24.30M38.24M
Total Debt2.89M4.54M3.45M4.00M4.13M4.38M
Total Liabilities5.62M8.41M6.95M7.02M8.60M9.99M
Stockholders Equity21.30M19.16M19.10M21.96M29.75M40.73M
Cash Flow
Free Cash Flow1.78M1.01M-1.76M-11.97M-13.60M11.73M
Operating Cash Flow1.95M1.11M-1.73M-11.96M-13.00M13.46M
Investing Cash Flow-1.17M-778.38K2.00M7.06M-628.00K-14.18M
Financing Cash Flow-461.86K-559.87K-637.10K-211.49K-357.95K16.19M

CleanSpace Holdings Ltd. Technical Analysis

Technical Analysis Sentiment
Negative
Last Price0.68
Price Trends
50DMA
0.66
Negative
100DMA
0.67
Negative
200DMA
0.66
Negative
Market Momentum
MACD
-0.03
Positive
RSI
31.07
Neutral
STOCH
23.41
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For AU:CSX, the sentiment is Negative. The current price of 0.68 is above the 20-day moving average (MA) of 0.62, above the 50-day MA of 0.66, and above the 200-day MA of 0.66, indicating a bearish trend. The MACD of -0.03 indicates Positive momentum. The RSI at 31.07 is Neutral, neither overbought nor oversold. The STOCH value of 23.41 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for AU:CSX.

CleanSpace Holdings Ltd. Peers Comparison

Overall Rating
UnderperformOutperform
Sector (51)
Financial Indicators
Name
Overall Rating
Market Cap
P/E Ratio
ROE
Dividend Yield
Revenue Growth
EPS Growth
51
Neutral
$7.86B-0.30-43.30%2.27%22.53%-2.21%
51
Neutral
AU$24.72M-2.93-103.74%14.84%39.64%
46
Neutral
AU$34.66M-1.42-74.00%23.31%-17.35%
44
Neutral
AU$101.92M-5.40-31.98%34.20%-23.90%
44
Neutral
AU$164.04M-15.03-70.55%-257.32%
43
Neutral
AU$44.96M25.33-2.50%25.72%84.69%
41
Neutral
AU$54.46M-4.24-128.19%-14.25%-22.83%
* Healthcare Sector Average
Performance Comparison
Ticker
Company Name
Price
Change
% Change
AU:CSX
CleanSpace Holdings Ltd.
0.57
0.09
18.75%
AU:IPD
Impedimed Limited
0.02
-0.03
-61.36%
AU:CYC
Cyclopharm Limited
0.85
-0.53
-38.55%
AU:MX1
Micro-X Ltd.
0.08
0.02
25.00%
AU:EMV
EMvision Medical Devices Ltd.
1.77
>-0.01
-0.28%
AU:CBL
Control Bionics Ltd.
0.06
0.02
42.86%

CleanSpace Holdings Ltd. Corporate Events

CleanSpace outlines 1HFY26 results and cautions on forward-looking disclosures
Feb 25, 2026

CleanSpace Holdings has released its results presentation for the half year ended 31 December 2025, outlining its financial performance and operational developments for 1HFY26. The document emphasises that figures are prepared under IFRS, includes non-IFRS measures such as EBITDA and free cash flow to illustrate underlying performance, and notes that past performance should not be seen as guidance for future results.

The company stresses that the presentation is informational only, not an offer or financial product advice, and that it may contain forward-looking statements subject to uncertainty and change. CleanSpace also highlights that the material is current only as at the presentation date, may be updated without notice, and has been authorised for release by its board, reinforcing formal governance over its market communications.

The most recent analyst rating on (AU:CSX) stock is a Hold with a A$0.58 price target. To see the full list of analyst forecasts on CleanSpace Holdings Ltd. stock, see the AU:CSX Stock Forecast page.

CleanSpace Delivers Margin-Strong H1 FY26 as Europe Drives Growth and Outlook Tightens
Feb 25, 2026

CleanSpace reported H1 FY26 revenue of $10.1 million, up 10% year on year, with gross margin improving to 75% and cash at bank rising 18% to $9.8 million, indicating sustained growth and strong unit economics. Operating EBITDA remained slightly negative at -$0.3 million but improved 23% versus the prior comparable period as the company balanced disciplined cost control with investment for future expansion.

Europe continued to be the main growth engine with sales up 26% to $6.7 million, driven by strong gains in Western Europe and the Nordics, while APAC and rest of world revenue fell 22% due to prior-year one-offs and slower Australian pipeline development. Management upgraded its FY26 outlook to target about 15% revenue growth, mid-70% gross margins, positive operating EBITDA in the second half and full-year positive cash flow, while committing to reinvest surplus cash to support international growth and market penetration.

The most recent analyst rating on (AU:CSX) stock is a Hold with a A$0.58 price target. To see the full list of analyst forecasts on CleanSpace Holdings Ltd. stock, see the AU:CSX Stock Forecast page.

CleanSpace Swings to Interim Profit on One-Off Loan Remeasurement Gain
Feb 25, 2026

CleanSpace Holdings Limited reported a strong turnaround for the half-year to 31 December 2025, with revenue from ordinary activities rising 9.7% to $10.1 million and net profit after tax swinging to $1.84 million from a $0.40 million loss a year earlier. Net tangible assets per share improved to $0.27 from $0.24, while the company again refrained from declaring or paying any dividends in the period.

The headline profit growth of 554.5% was largely driven by a one-off gain from derecognising a loan owed to NSW Health Administration Corporation, after the liability was remeasured and written down to nil. Excluding this non-recurring accounting adjustment, underlying performance would have reflected a deeper loss, highlighting that the statutory result overstates the company’s operational improvement for stakeholders assessing its core earnings.

The most recent analyst rating on (AU:CSX) stock is a Hold with a A$0.58 price target. To see the full list of analyst forecasts on CleanSpace Holdings Ltd. stock, see the AU:CSX Stock Forecast page.

CleanSpace Secures $891,000 R&D Rebate to Drive Respiratory Tech Innovation
Feb 23, 2026

CleanSpace Holdings Limited, an Australian manufacturer of premium respiratory protection solutions for industrial and healthcare markets, continues to invest in advanced powered air purifying respirator technology developed by a team of biomedical engineers. Its focus on differentiated design and approved products aims to enhance worker safety and health outcomes across demanding end markets.

The company has received an $891,000 cash rebate under the Australian federal government’s R&D Tax Incentive program for the financial year ended 30 June 2025, with funds earmarked for ongoing product research and development. The rebate reinforces CleanSpace’s position as an innovation-led player in the PAPR segment, supporting continued product advancement and potentially strengthening its competitive edge and value proposition for industrial customers and frontline workers.

The most recent analyst rating on (AU:CSX) stock is a Hold with a A$0.56 price target. To see the full list of analyst forecasts on CleanSpace Holdings Ltd. stock, see the AU:CSX Stock Forecast page.

CleanSpace seeks ASX quotation for new share issuance
Feb 23, 2026

CleanSpace Holdings has applied to the ASX for quotation of 490,530 additional ordinary fully paid shares, with an issue date of 17 February 2026. The move modestly increases the company’s free float and equity base, signalling ongoing capital management activity that may enhance liquidity for existing shareholders and support future corporate initiatives.

The newly issued securities arise from the exercise or conversion of existing options or other convertible instruments into ordinary shares. This conversion-based issuance suggests prior commitments are being crystallised into equity, slightly diluting existing holdings while potentially aligning capital structure with long-term strategic or employee incentive arrangements.

The most recent analyst rating on (AU:CSX) stock is a Hold with a A$0.56 price target. To see the full list of analyst forecasts on CleanSpace Holdings Ltd. stock, see the AU:CSX Stock Forecast page.

CleanSpace Writes Off NSW Health Loan, Booking $2.8m Gain
Feb 22, 2026

CleanSpace Holdings has reclassified a $2.8 million funding loan from the NSW Health Administration Corporation, awarded under the Medical Device Funding program in 2019, from a long-term liability to nil on its balance sheet as at 31 December 2025. The move follows the board’s assessment that the respirator project supported by the loan has not met commercial success milestones, with related sales contributing less than 0.5% of revenue in recent years and cumulative EBITDA remaining negative.

The accounting change, made under AASB 9 guidance and backed by external expert advice, will result in a $2.8 million uplift in ‘other gains’ in CleanSpace’s H1FY26 profit and loss statement. Management will reassess the likelihood of future commercial success and potential cash flows at each annual reporting date, with any renewed liability to be remeasured through the profit and loss, underscoring a more conservative stance on the project’s prospects while modestly improving near-term earnings.

The most recent analyst rating on (AU:CSX) stock is a Hold with a A$0.56 price target. To see the full list of analyst forecasts on CleanSpace Holdings Ltd. stock, see the AU:CSX Stock Forecast page.

CleanSpace Issues 863,000 Unquoted Restricted Share Awards Under Employee Scheme
Feb 6, 2026

CleanSpace Holdings has notified the ASX that it has issued 863,000 unquoted restricted share awards under its employee incentive scheme. The new equity awards, which are not intended to be quoted on the exchange, represent a further use of stock-based compensation to reward and retain staff, modestly diluting existing shareholders while aligning employees’ interests more closely with the company’s long-term performance.

The most recent analyst rating on (AU:CSX) stock is a Hold with a A$0.70 price target. To see the full list of analyst forecasts on CleanSpace Holdings Ltd. stock, see the AU:CSX Stock Forecast page.

CleanSpace Sets Date for FY26 Half-Year Results Briefing
Feb 1, 2026

CleanSpace Holdings has scheduled the release of its half-year results for the period ended 31 December 2025 on 26 February 2026, with the chairman, CEO and CFO to brief investors and analysts via webcast and telephone. The planned briefing underscores the company’s ongoing communication with the market as it pursues growth in its specialised respiratory protection niche, with stakeholders likely to focus on how continued R&D investment and product differentiation are translating into financial performance and industry positioning.

The most recent analyst rating on (AU:CSX) stock is a Hold with a A$0.70 price target. To see the full list of analyst forecasts on CleanSpace Holdings Ltd. stock, see the AU:CSX Stock Forecast page.

Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.Date of analysis: Nov 28, 2025